Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erika Vacchelli

Showing results (1-10 of 90) with videos related to

Pageof 9
Sort By:
Oncoimmunology|May 12, 2020
The ambiguous role of FPR1 in immunity and inflammationErika Vacchelli, Julie Le Naour, Guido Kroemer
Oncoimmunology|July 30, 2013
Current trends of anticancer immunochemotherapyErika Vacchelli, Nicole Prada, Oliver Kepp, et al.
Frontiers in Oncology|June 2, 2012
Cell death signaling and anticancer therapyLorenzo Galluzzi, Ilio Vitale, Erika Vacchelli, et al.
Oncoimmunology|September 16, 2020
Trial watch: STING agonists in cancer therapyJulie Le Naour, Laurence Zitvogel, Lorenzo Galluzzi, et al.
Oncoimmunology|September 20, 2018
TumGrowth: An open-access web tool for the statistical analysis of tumor growth curvesDavid P Enot, Erika Vacchelli, Nicolas Jacquelot, et al.
Oncoimmunology|September 16, 2020
Trial watch: TLR3 agonists in cancer therapyJulie Le Naour, Lorenzo Galluzzi, Laurence Zitvogel, et al.
Oncoimmunology|July 29, 2016
Yet another pattern recognition receptor involved in the chemotherapy-induced anticancer immune response: Formyl peptide receptor-1Erika Vacchelli, Yuting Ma, Elisa E Baracco, et al.
Oncoimmunology|September 16, 2020
Trial watch: IDO inhibitors in cancer therapyJulie Le Naour, Lorenzo Galluzzi, Laurence Zitvogel, et al.
Cancer Research|May 20, 2016
Impact of Pattern Recognition Receptors on the Prognosis of Breast Cancer Patients Undergoing Adjuvant ChemotherapyErika Vacchelli, David P Enot, Federico Pietrocola, et al.
Oncoimmunology|September 26, 2015
Autocrine signaling of type 1 interferons in successful anticancer chemotherapyErika Vacchelli, Antonella Sistigu, Takahiro Yamazaki, et al.
Pageof 9

Showing results (1-10 of 90) with videos related to

Sort By:
Pageof 9
Oncoimmunology|May 12, 2020
The ambiguous role of FPR1 in immunity and inflammationErika Vacchelli, Julie Le Naour, Guido Kroemer
Oncoimmunology|July 30, 2013
Current trends of anticancer immunochemotherapyErika Vacchelli, Nicole Prada, Oliver Kepp, et al.
Frontiers in Oncology|June 2, 2012
Cell death signaling and anticancer therapyLorenzo Galluzzi, Ilio Vitale, Erika Vacchelli, et al.
Oncoimmunology|September 16, 2020
Trial watch: STING agonists in cancer therapyJulie Le Naour, Laurence Zitvogel, Lorenzo Galluzzi, et al.
Oncoimmunology|September 20, 2018
TumGrowth: An open-access web tool for the statistical analysis of tumor growth curvesDavid P Enot, Erika Vacchelli, Nicolas Jacquelot, et al.
Oncoimmunology|September 16, 2020
Trial watch: TLR3 agonists in cancer therapyJulie Le Naour, Lorenzo Galluzzi, Laurence Zitvogel, et al.
Oncoimmunology|July 29, 2016
Yet another pattern recognition receptor involved in the chemotherapy-induced anticancer immune response: Formyl peptide receptor-1Erika Vacchelli, Yuting Ma, Elisa E Baracco, et al.
Oncoimmunology|September 16, 2020
Trial watch: IDO inhibitors in cancer therapyJulie Le Naour, Lorenzo Galluzzi, Laurence Zitvogel, et al.
Cancer Research|May 20, 2016
Impact of Pattern Recognition Receptors on the Prognosis of Breast Cancer Patients Undergoing Adjuvant ChemotherapyErika Vacchelli, David P Enot, Federico Pietrocola, et al.
Oncoimmunology|September 26, 2015
Autocrine signaling of type 1 interferons in successful anticancer chemotherapyErika Vacchelli, Antonella Sistigu, Takahiro Yamazaki, et al.
Pageof 9